MedTrace Logo

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

NCT00567047 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2009-03-25

No results posted yet for this study

Summary

This study will evaluate the pharmacokinetics of vildagliptin and its metabolites in patients with mild, moderate or severe renal impairment and healthy volunteers.

Conditions

  • Type-2 Diabetes

Interventions

DRUG

vildagliptin

Sponsors & Collaborators

Principal Investigators

  • Novartis · Novartis investigative site

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-01-31

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00567047 on ClinicalTrials.gov